Document Detail


Best practice options for hair removal in patients with unwanted facial hair using combination therapy with laser: guidelines drawn up by an expert working group.
MedLine Citation:
PMID:  20587996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hirsutism is a common disorder affecting between 5 and 15% of the population. One of the most devastating consequences of hirsutism is the presence of unwanted facial hair. Treatment of hirsutism involves a two-pronged approach: treating the underlying cause and reduction of visible hair. Laser hair removal is one of the most effective options for reducing visible hair, however, it may not be wholly effective in all patients and combination therapy may need to be considered. Pharmacological therapy is often used in combination with mechanical hair removal due to the time needed for the drug treatment to demonstrate visible results. Clinical data investigating the use of laser treatment in combination with other treatments has focused on laser with topical eflornithine. The expert working group reviews existing data and provides guidance on the use of eflornithine in combination with laser for resistant hirsutism.
Authors:
M Lapidoth; C Dierickx; S Lanigan; U Paasch; A Campo-Voegeli; S Dahan; L Marini; M Adatto;
Related Documents :
3809266 - The office treatment of tattoos: a simple and effective method.
3620786 - Congenital "giant" naevus: a preliminary report of a new surgical approach.
11350676 - Intense pulsed light treatment for chronic facial erythema of systemic lupus erythemato...
11096386 - Epidermal cooling crystal collar device for improved results and reduced side effects o...
12578446 - Outcomes in suction coagulator adenoidectomy.
20537626 - Urinary hmg (meropur) versus recombinant fsh plus recombinant lh (pergoveris) in ivf: a...
Publication Detail:
Type:  Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't     Date:  2010-06-26
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  221     ISSN:  1421-9832     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-09     Completed Date:  2010-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  34-42     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Affiliation:
Dermatology Department, Rabin Medical Center, Petach Tikva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Combined Modality Therapy / adverse effects
Eflornithine / therapeutic use
Face
Female
Hair Removal / adverse effects,  methods*
Hirsutism / drug therapy,  therapy*
Humans
Laser Therapy / adverse effects,  methods
Treatment Outcome
Chemical
Reg. No./Substance:
70052-12-9/Eflornithine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interstitial deletion of chromosome 7q and the lack of association with Down syndrome screening mark...
Next Document:  Nerve growth factor promotes the survival of goat preantral follicles cultured in vitro.